ReviewOncoTargets and therapy2018
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.
Review in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.Bone marrow transplantation · 2025Pooled it
- The specificity trap in routine tumor biomarker interpretation: Advancing the 3PM-based clinical decision framework to benefits of patients.The EPMA journal · 2026Review
- Pathobiological link between CD30 and abnormal lymphocytes in adult T-cell leukemia/lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Therapeutic antibodies in oncology: an immunopharmacological overview.Cancer immunology, immunotherapy : CII · 2024Review
- Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.Frontiers in immunology · 2024Review
- Screening, optimization, and ADMET evaluation of HCJ007 for pancreatic cancer treatment through active learning and dynamics simulation.Frontiers in chemistry · 2024Article
- Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2024Review
- Article
- A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: A potential targeted immunotherapy.PloS one · 2023Article
- Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy.Frontiers in oncology · 2023Article
- A Case of Anaplastic Large Cell Lymphoma Misdiagnosed with Keloid.Clinical, cosmetic and investigational dermatology · 2023Article
- Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.PharmacoEconomics - open · 2022Article
- Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.Frontiers in oncology · 2022Review
- Review
- Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin.Molecular and clinical oncology · 2021Article
- Review
- Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology.Journal of medicinal chemistry · 2020Review
- Perplexing Role of P-Glycoprotein in Tumor Microenvironment.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%-3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%-80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody-drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.